

Table S1. Patient characteristics of primary AML patient samples

Patients	Gender	Age (year)	Disease status	FAB subtype	Cytogenetics	Blast purity (%)	Gene mutation
AML#136	Female	44	Newly diagnosed	M2	46,XX(20)	80	CEBPA Double mutation
AML#137	Female	62	Newly diagnosed	M2	45,X,-X,t(8;21)(q22;q22)	47	RUNX1-RUNX1T1
AML#138	Female	46	Relapsed	M4	46,XX	68.5	NPM-1
AML#139	Female	44	Relapsed	M5	46,XX	84.5	NPM-1, FLT3-ITD, IDH2, DNMT3A
AML#140	Female	33	Newly diagnosed	M3	46,XX,t(15;17)(q22;q21)	97.5	PML-RAR α
AML#141	Female	40	Newly diagnosed	M5	46,XX	39	NA
AML#142	Female	64	Newly diagnosed	M2	46,XX	53.5	DNMT3A, PHF6, STAG2, TET2 mutation
AML#143	Male	72	Newly diagnosed	M5	46,XY	83.5	DNMT3A, NPM1, NRAS, SF3B1, TET2 mutation
AML#144	Female	64	Newly diagnosed	M4	46,XX	20.5	DNMT3A, FLT3-ITD, NPM1, TET2 mutation
AML#145	Male	41	Newly diagnosed	M5	46,XY,t(6;11)(q27;q23)	88	KRAS mutation
AML#146	Female	20	Relapsed	M2	46,XX	62.5	CEBPA Double mutation
AML#147	Male	41	Newly diagnosed	M2	46,XY,t(8;21)(q22;q22)	69	TET2 mutation
AML#148	Male	54	Relapsed	M5	46,XY	93	NPM1, FLT3-ITD, DNMT3A mutation
AML#149	Male	48	Newly diagnosed	M4	46,XY	55.5	FLT3-ITD mutation
AML#150	Male	48	Newly diagnosed	M2	46,XY	68	CEBPAdm, IDH2
AML#151	Male	26	Newly diagnosed	M3	46,XY	88	
AML#152	Female	49	Newly diagnosed	M5	46,XX	85	DNMT3A, NPM1
AML#153	Male	54	Relapsed	M2	46,XY	29	RUNX1, IDH2, DNMT3A
AML#154	Female	75	Untreated	M5	NA	37	
AML#155	Male	68	Newly diagnosed	M5	46,XY	96.5	FLT3-ITD, NPM1, DNMT3A
AML#156	Female	21	Relapsed	M3	46,XX	88	
AML#157	Male	59	Newly diagnosed	M3	44,XY,-1,-12,add(16p),add(17q)	95.5	N-RAS, TET2, TP53
AML#158	Male	53	Relapsed	M2	NA	98	NA
AML#166	Male	57	Newly diagnosed	M5	46,XY	66	DNMT3A, TET2, NPM-1
AML#170	Female	50	Newly diagnosed	M4	46,XX,t(3;3)(q21;q26)	72	SF3B1
AML#171	Female	59	Newly diagnosed	M2	47,XX,+8	60.5	FLT3-ITD, DNMT3A
AML#172	Female	54	Newly diagnosed	M2	46,XX	58.5	CEBPAdm, IDH2, N-RAS
AML#173	Female	66	Newly diagnosed	M2	46,XX	89.5	FLT3-ITD, DNMT3A
AML#174	Female	1	Newly diagnosed	M1	46,XX	87	
AML#175	Male	4	Newly diagnosed	M2	46,XY	56.5	
AML#176	Male	35	Newly diagnosed	M2	46,XY	85	GATA2, c-Kit
AML#177	Male	5	Newly diagnosed	M2	46,XY	90	MLL-AF9

Table S1 continued

Patients	Gender	Age (year)	Disease status	FAB subtype	Cytogenetics	Blast purity (%)	Gene mutation
AML#180	Male	68	Relapsed	M5	46,XY	96	Flt3-ITD, NPM1, DNMT3A
AML#181	Female	30	Newly diagnosed	M4	46,XX	77.5	Flt3-ITD, NPM1, IDH2, N-RAS
AML#182	Female	44	Newly diagnosed	M2	45,X,-X,t(6;7)(q25;q22),t(8;21)(q22;q22)	27	MPL W515L
AML#183	Female	47	Relapsed	M4	46,XX	88	NPM1, DNMT3A, IDH2, PTPN11
AML#184	Female	12	Newly diagnosed	M3	46,XX,t(15;17)(q22;q21)	93.5	PML/RARa
AML#185	Female	37	Newly diagnosed	M2	46,XX	87.5	FLT3-ITD, NPM1, IDH2
AML#186	Female	41	Newly diagnosed	M2	46,XX	30.5	Flt3-ITD, NPM1, DNMT3A, TP53
AML#187	Male	50	Newly diagnosed	M4	47,XY,+8	96.5	FLT3-ITD
AML#188	Female	55	Newly diagnosed	M3	46,XX,t(15;17)(q22;q21)	93	FLT3-ITD, SH2B3
AML#189	Male	79	Newly diagnosed	M5	46,XY	74.5	ASXL1, RUNX1, CEBPAsm, TET2, SRSF2, STAT5B, CREBBP, PHF6
AML#190	Female	51	Newly diagnosed	M4	NA	94	NA
AML#192	Female	1	Newly diagnosed	M4/M5	46,XX	29.5/17.5	
AML#196	Female	40	Newly diagnosed	M5	46,XX	98	NPM-1, FLT3-ITD, DNMT3A
AML#197	Male	21	Newly diagnosed	M2	46,XY,t(8;21)(q22;q22)	37	CSF3R, FLT3-ITD, TET-2
AML#198	Female	44	Newly diagnosed	M2	46,XX,t(8;21)(q22;q22)	68	ASXL1,K-RAS,N-RAS
AML#199	Female	47	Relapsed	M4	46,XX	98	NPM1, FLT3-ITD, IDH2
AML#200	Male	44	Newly diagnosed	M2	46,XY	77	CEBPAdm, FLT3-ITD
AML#231	Male	17	Newly diagnosed		46, XY, der(19)t(1;19)(q23;p13), +21[16]	74	
AML#235	Female	33	Newly diagnosed	M4/M5	46, XX	87	NPM1
AML#237	Male	56	Relapsed			88	
AML#248	Male	16	Newly diagnosed	AML	45, X, -Y[20]	79	CEBPA, NRAS, PTPN11
AML#250	Male	44	Newly diagnosed	M5	46,XY,add(9)(q34)[18]/46,XY[2]	85.5	WT1, PRAME, ELANE, IDH2, SH2B3, TET2
AML#251	Female	67	Newly diagnosed	AML	46, XX[20]	87	FLT3-ITD, ETNK1, ETV6, PTPN11, RUNX1, RUNX1
AML#252	Female	39	Newly diagnosed	M5	46, XX[10]	97.5	NA
AML#253	Male	38	Newly diagnosed	AML	46, XY[20]	66.5	CEBPA, KMT2C, PDGFRA
AML#256	Male	57	Newly diagnosed	M4/M5	47,XY,+8[20]	80.5	MLL-PTD(+); DNMT3A, SH2B3, FLT3-TKD, TCF, RUNX1